Physician profile
Elizabeth A Richardson
NPI 1871913186
$66,283.04
in general payments reported to CMS, 2019-2025
32 companies · $40K in 2025
The $40K reported for 2025 was more than what 83% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $208 · 2021: $122 · 2022: $307 · 2023: $1,141 · 2024: $24K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Food and Beverage: $4,713 · Travel and Lodging: $2,206 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,136.00 |
| Food and Beverage | $4,713.42 |
| Travel and Lodging | $2,206.33 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $47,390.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $15,619.06 | 2019-2025 | Livdelzi, Epclusa, Vemlidy |
| Abbvie INC. | $491.18 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $409.91 | 2022-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $348.18 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $321.42 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $270.84 | 2023-2025 | Stelara, Tremfya, Simponi |
| Mallinckrodt Hospital Products INC. | $206.46 | 2023-2024 | Terlivaz |
| Novo Nordisk INC | $175.40 | 2025 | Wegovy |
| Mirum Pharmaceuticals, INC. | $138.45 | 2024-2025 | Livmarli |
| Lilly USA, LLC | $125.41 | 2023-2024 | Mounjaro, Omvoh |
| Alcresta Therapeutics, INC. | $121.84 | 2023 | Relizorb |
| Aimmune Therapeutics, INC. | $93.25 | 2025 | Zenpep |
| Glaxosmithkline, LLC. | $58.92 | 2023 | |
| Ardelyx, INC. | $52.95 | 2023-2025 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $50.64 | 2019 | |
| Qol Medical, LLC | $49.48 | 2025 | Sucraid |
| Echosens North America, INC. | $36.84 | 2025 | Fibroscan |
| Fujifilm Healthcare Americas Corporation | $34.71 | 2025 | |
| Celgene Corporation | $32.20 | 2022 | |
| Braintree Laboratories, INC. | $30.65 | 2022-2025 | Suflave, Sutab |
| Celltrion USA INC. | $30.18 | 2025 | Vegzelma |
| Pfizer INC. | $27.09 | 2024 | |
| Shire North American Group INC | $23.72 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.04 | 2023 | Dupixent |
| Amgen INC. | $22.00 | 2025 | Uplizna |
| Merck Sharp & Dohme LLC | $18.37 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.89 | 2025 | Voquezna |
| Veloxis Pharmaceuticals, INC. | $17.65 | 2025 | Envarsus |
| Amag Pharmaceuticals, INC. | $15.79 | 2019 | |
| Evoke Pharma, INC. | $15.51 | 2024 | |
| Endo Pharmaceuticals INC. | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.